Showing 3671-3680 of 4063 results for "".
- Analysis: Ambulatory Surgery Centers Reduce Medicare Costs by More than $4 Billion Each Yearhttps://modernod.com/news/analysis-ambulatory-surgery-centers-reduce-medicare-costs-by-more-than-4-billion-each-year/2478306/New analysis of Medicare payment data shows that ambulatory surgery centers (ASC) reduced Medicare costs by $28.7 billion from 2011 through 2018 by providing services to beneficiaries that otherwise would have been provided in higher-cost hospital outpatient departments (HOPD), according to the A
- Nicox Announces Senior Management Changehttps://modernod.com/news/nicox-announces-senior-management-change/2478295/Nicox announced that Tomas Navratil, PhD, Executive Vice President & Head of Research & Development of the Nicox Group and General Manager of Nicox Ophthalmics, will be leaving the company on October 16, 2020 to pursue other opportunities. Nicox has initiated a search for a successor. In
- Santen Acquires Eyevance Pharmaceuticalhttps://modernod.com/news/santen-acquires-eyevance-pharmaceutical/2478289/In a move to enter the US pharmaceuticals market and expand its global presence, Santen announced it has acquired Eyevance Pharmaceutical for $225 million in cash. In the deal, Santen Holdings U.S. Inc., a wholly-owned subsidiary of Santen, will acquire all of the outstanding shares of Ey
- Kala Pharmaceuticals to Host Key Opinion Leader Symposium on Unmet Need in Dry Eye Disease and Potential for Eysuvishttps://modernod.com/news/kala-pharmaceuticals-to-host-key-opinion-leader-symposium-on-unmet-need-in-dry-eye-disease-and-potential-for-eysuvis/2478270/Kala Pharmaceuticals announced that it will host a key opinion leader symposium on the unmet need in dry eye disease and the potential for Eysuvis as a short-term treatment for the signs and symptoms of the disease. The event will be held virtually on Thursday, September 17, 2020, beginning at 8
- AstraZeneca Must Explain Spinal Ailment to Resume Vaccine Trialhttps://modernod.com/news/astrazeneca-must-explain-spinal-ailment-to-resume-vaccine-trial/2478268/A day after pausing its COVID-19 vaccine trials due to a possible serious neurological problem in one patient, AstraZeneca faced numerous questions about what exactly caused the issue and whether it could be related to the vaccine, according to a Bloomberg News
- AstraZeneca Pauses COVID-19 Vaccine Trial Amid Safety Concernhttps://modernod.com/news/astrazeneca-pauses-covid-19-vaccine-trial-amid-safety-concern/2478258/Shares in AstraZeneca fell as much as 6% on Tuesday after the company confirmed that a phase 3 trial of its experimental COVID-19 vaccine AZD1222 has been put on hold due to a possible safety issue. AstraZeneca called the move “a routine action which has to happen whenever there is a potent
- Analysis Finds Corticosteroids Cut Risk of Death in Critically Ill COVID-19 Patientshttps://modernod.com/news/analysis-finds-corticosteroids-cut-risk-of-death-in-critically-ill-covid-19-patients/2478240/Results of a meta-analysis published Wednesday in JAMA suggest that the use of systemic corticosteroids in critically ill patients with COVID-19 is associated with lower 28-day all-cause mortality compared to usual care or placebo. Study author Jonathan Sterne noted that the benefit was
- Medical Optometry America to Open First Practice Location in Southcentral Pennsylvaniahttps://modernod.com/news/medical-optometry-america-to-open-first-practice-location-in-southcentral-pennsylvania/2478237/Medical Optometry America (MOA) announced their first practice location will open in Shrewsbury, Pennsylvania in late 2020 and will be led by MOA’s Regional Clinical Director Leslie O’Dell, OD, FAAO. As the first national optometric brand focused exclusively on medical eye care, MOA is lau
- NIH Panel Finds “Insufficient” Data to Support Use of Plasma for COVID-19https://modernod.com/news/nih-panel-finds-insufficient-data-to-support-use-of-plasma-for-covid-19/2478235/A panel of the National Institutes of Health (NIH) concluded that “there are insufficient data to recommend either for or against the use of convalescent plasma for the treatment of COVID-19.” The review by the COVID-19 Treatment Guidelines Panel comes shortly after the FDA issued an
- Zeiss Launches Virtual Optometry Hubhttps://modernod.com/news/zeiss-launches-virtual-optometry-hub/2478226/Zeiss announced it is launching the Zeiss Virtual Optometry Hub on September 20-21. In the all-new 360° experience, visitors will be able to take a walk through the Zeiss Virtual Practice and see how diagnostic equipment and data management can integrate seamlessly to provide a sophisticated prac